Tanaka Kazuhiro, Mizusawa Junki, Fukuda Haruhiko, Araki Nobuhito, Chuman Hirokazu, Takahashi Mitsuru, Ozaki Toshifumi, Hiruma Toru, Tsuchiya Hiroyuki, Morioka Hideo, Hatano Hiroshi, Iwamoto Yukihide
Department of Endoprosthetic Surgery, Oita University, Oita.
JCOG Data Center, Center for Research Administration and Support, National Cancer Center, Tokyo.
Jpn J Clin Oncol. 2015 Jun;45(6):555-61. doi: 10.1093/jjco/hyv042. Epub 2015 Apr 2.
The efficacy of perioperative chemotherapy for soft tissue sarcomas is controversial and only a few prospective studies of pre-operative chemotherapy for soft tissue sarcomas in the extremities have been reported. We therefore carried out Phase II study of perioperative chemotherapy for patients with soft tissue sarcomas in the extremities.
Patients with Stage III non-round cell soft tissue sarcomas in the extremities were eligible. The patients were treated with pre-operative chemotherapy consisting doxorubicin 60 mg/m(2) and ifosfamide 10 g/m(2) for three courses. After the tumor resection, two additional courses of the same regimen were carried out.
A total of 72 patients were enrolled and 70 patients were eligible. The median age of the patients was 49 years. The major pathological subtypes were synovial sarcoma in 20 and undifferentiated pleomorphic sarcoma in 17 patients. The protocol treatments were completed in 74% of the eligible cases. The 2 and 5-year progression-free survival rates were 75.7% (95% CI, 63.9-84.1%) and 63.8% (95% CI, 51.3-73.9%), respectively. The 5-year overall survival was 82.6% (95% CI, 71.3-89.7%). There was no treatment-related death. Grade 3 or 4 hematological toxicities (leukopenia and neutropenia) were observed in most of the patients.
Although the toxicities of the regimen were significant, pre-operative chemotherapy followed by post-operative chemotherapy using doxorubicin and high-dose ifosfamide was feasible. The outcome of the trial for the patients with high-grade soft tissue sarcomas in the extremities was favorable, and this regimen is promising for further investigation. This trial was registered at the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) as C000000096.
软组织肉瘤围手术期化疗的疗效存在争议,仅有少数关于肢体软组织肉瘤术前化疗的前瞻性研究报道。因此,我们开展了肢体软组织肉瘤患者围手术期化疗的II期研究。
符合条件的患者为III期非圆形细胞肢体软组织肉瘤患者。患者接受术前化疗,方案为多柔比星60mg/m²和异环磷酰胺10g/m²,共三个疗程。肿瘤切除后,再进行两个疗程的相同方案化疗。
共纳入72例患者,70例符合条件。患者的中位年龄为49岁。主要病理亚型为20例滑膜肉瘤和17例未分化多形性肉瘤。74%的符合条件病例完成了方案治疗。2年和5年无进展生存率分别为75.7%(95%CI,63.9 - 84.1%)和63.8%(95%CI,51.3 - 73.9%)。5年总生存率为82.6%(95%CI,71.3 - 89.7%)。无治疗相关死亡。大多数患者观察到3级或4级血液学毒性(白细胞减少和中性粒细胞减少)。
尽管该方案毒性显著,但多柔比星和高剂量异环磷酰胺术前化疗后行术后化疗是可行的。该试验对于肢体高级别软组织肉瘤患者的结果良好,该方案有望进一步研究。本试验已在日本大学医学情报网络临床试验注册中心(www.umin.ac.jp/ctr/)注册,注册号为C000000096。